NDA 206910 · Novartis Pharms Corp
Jadenu
Deferasirox · Oral · Iron Chelator
Accelerated approvalOrphanLast checked: Nov 20, 2026Latest source record: Feb 11, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Mar 30, 2015
Approved uses
6
Original approval plus efficacy supplements
Registered trials
97
15 Phase 3, 2 recruiting
FAERS reports
6,732
4,874 serious, 1,125 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RENAL FAILURE, HEPATIC FAILURE, and GASTROINTESTINAL HEMORRHAGE Renal Failure JADENU can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders. Evaluate baseline renal function prior to starting or increasing JADENU dosing in all patients. JADENU is contraindicated in adult and pediatric patients with eGFR less than 40 mL/min/1.73 m 2 . Measure serum creatinine in duplicate prior to initiation of therapy. Monitor renal function at least monthly. For patients with baseline renal impairment or increased risk of acute renal failure, monitor renal function weekly for the first month, then at least monthly. Reduce the starting dose in patients with preexisting renal disease. During therapy, increase the frequency of monitoring and modify the dose for patients with an increased risk of...
What it is approved for
From the label in effect Dec 11, 2025.
JADENU is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) JADENU is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of JADENU when administered with other iron chelation therapy have not been established. ( 1.3 ) 1.1 Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload) JADENU is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. 1.2 Treatment of Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes JADENU is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L. 1.3 Limitations of Use The safety and efficacy of JADENU when administered with other iron chelation therapy have not been established.
Mechanism: JADENU (deferasirox) is an orally active chelator that is selective for iron (as Fe 3+ ). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper, there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 23, 2020 Supplement 15 · Efficacy OrphanLetterLabelMedication Guide
- Jul 26, 2019 Supplement 12 · Efficacy OrphanLetterLabelMedication Guide
- May 24, 2019 Supplement 14 · Efficacy · priority review OrphanLabelLetter
- Dec 12, 2018 Supplement 9 · Efficacy · priority review OrphanLabelLetter
- May 11, 2018 Supplement 6 · Efficacy OrphanLabelLetter
- Mar 30, 2015 Original approval · Type 5 - New Formulation or New Manufacturer Accelerated approvalLabelReviewLetter
3 products under this application
- JADENU · DEFERASIROX 180MG · TABLET, ORAL · Prescription · TE AB
- JADENU · DEFERASIROX 360MG · TABLET, ORAL · Prescription · TE AB
- JADENU · DEFERASIROX 90MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Deferasirox" as an intervention, any sponsor and status, largest first.
- A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron OverloadPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00171821 · 1,784 participants · Start Apr 2005 · Primary completion May 2009
Drug: Deferasirox · For: Transfusion-dependent Iron Overload
Sites: Adelaide, Australia; Camperdown, Australia; Clayton, Australia · 97 sites in all
- Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron OverloadPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00235391 · 1,683 participants · Start Oct 2005 · Primary completion Oct 2008
Drug: Deferasirox · For: Thalassemia; Sickle Cell Disease; Diamond Blackfan Anemia and 1 more
Sites: Little Rock, Arkansas; Berkeley, California; Orange, California · 141 sites in all
- Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood TransfusionsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00061750 · 595 participants · Start May 2003 · Primary completion Nov 2004
Drug: ICL670; deferoxamine · For: Beta-Thalassemia
Sites: Los Angeles, California; Oakland, California; Stanford, California · 7 sites in all
- An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron OverloadPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00171210 · 506 participants · Start Oct 2004 · Primary completion Apr 2008
Drug: Deferasirox · For: Transfusional Iron Overload in β-thalassemia
Sites: Los Angeles, California; Oakland, California; Stanford, California · 49 sites in all
- Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric PatientsPivotal-lookingCompleted
Consorzio per Valutazioni Biologiche e FarmacologicheAcademic, hospital or other
NCT01825512 · 435 participants · Start Mar 17, 2014 · Primary completion Sep 21, 2017
Drug: Deferiprone; Deferasirox · For: Chronic Iron Overload
Sites: Lushnje, Albania; Tirana, Albania; Nicosia, Cyprus · 22 sites in all
- Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major ThalassemiaPivotal-lookingCompleted
Beni-Suef UniversityAcademic, hospital or other
NCT04292314 · 350 participants · Start Nov 1, 2019 · Primary completion Dec 20, 2020
Drug: Omega 3; Nigella Sativa Oil and 3 more · For: Iron Overload; Oxidative Stress; Thalassemia Major
Sites: Banī Suwayf, Egypt; Mecca, Saudi Arabia · 4 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT00564941 · 309 participants (planned) · Start Dec 2007 · Primary completion Jul 2011
Drug: deferasirox · For: Myelodysplastic Syndromes; Beta-Thalassemia
Sites: Budapest, Hungary; Debrecen, Hungary; Pécs, Hungary · 4 sites in all
- A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional HemosiderosisPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00171171 · 252 participants · Start May 2004 · Primary completion Nov 2006
Drug: deferasirox · For: Beta-Thalassemia; Hemosiderosis
Sites: Cairo, Egypt; Beirut, Lebanon; Muscat, Oman · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death696
- sickle cell anaemia with crisis563
- diarrhoea478
- off label use419
- nausea335
- haemoglobin decreased312
- pyrexia310
- drug ineffective286
- fatigue272
- vomiting250
- anaemia216
- abdominal pain210
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 14 |
| 2009 | 16 |
| 2010 | 31 |
| 2011 | 37 |
| 2012 | 73 |
| 2013 | 44 |
| 2014 | 44 |
| 2015 | 213 |
| 2016 | 518 |
| 2017 | 585 |
| 2018 | 599 |
| 2019 | 658 |
| 2020 | 750 |
| 2021 | 675 |
| 2022 | 757 |
| 2023 | 536 |
| 2024 | 496 |
| 2025 | 368 |
| 2026 | 313 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Jadenu (Deferasirox)
2024 spending
$7.8M
Beneficiaries
94
512 claims
Per beneficiary
$82,603
$170.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $57,812,722 |
| 2021 | $23,693,409 |
| 2022 | $12,533,457 |
| 2023 | $8,881,640 |
| 2024 | $7,764,691 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Genetic polymorphisms influencing deferasirox pharmacokinetics, efficacy, and adverse drug reactions: a systematic review and meta-analysis.
Yampayon K, Anantachoti P, Chongmelaxme B, et al. · Front Pharmacol 2023 · Systematic Review
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Comparative effectiveness of adding omega-3 and Manuka honey combination to conventional therapy in preventing and treating oxidative stress in pediatric β-thalassemia major - a randomized clinical trial.
Gamaleldin M, Abraham I, Meabed M, et al. · Eur Rev Med Pharmacol Sci 2023 · Randomized Controlled Trial
- Oxidative stress markers and tissue iron overload after 12-months vitamin E supplementation for children with transfusion-dependent β-thalassemia on different iron chelators: A randomized placebo-controlled trial.
ElLaboudy MA, Saber MM, Adly AA, et al. · Clin Nutr 2025 · Randomized Controlled Trial
- Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.
Sarocchi M, Li J, Li X, et al. · Br J Haematol 2024 · Randomized Controlled Trial, Multicenter Study
- Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Ware RE, Helms RW · Blood 2012 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.